Results 61 to 70 of about 63,206 (209)
Introduction: Chronic hepatitis B (CHB) is a major cause of chronic liver diseases and tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), and entecavir (ETV) are recommended as primary treatments.
Sara Jeong, Hyun Phil Shin, Ha Il Kim
doaj +1 more source
Evidence-Based Study of Medication Compliance Project in Hiv Prevention Using Pre-Exposure Prophylaxis (Prep) Antivirals for HIV-Negative Males [PDF]
In 2012, emtricitabine/tenofovir was the only Food and Drug Administration-approved medication for pre-exposure prophylaxis (PrEP) used in human immunodeficiency virus (HIV) prevention.
Ho, Ming-Chun
core +1 more source
The Safety of Interferon‐Based Therapies in Chronic Hepatitis B Patients With Compensatory Cirrhosis
While nucleos(t)ide analog (Nuc) therapy is the standard for chronic hepatitis B, pegylated interferon‐alpha (Peg‐IFN‐α) provides unique advantages, including finite treatment duration and long‐term benefits. However, its use in patients with compensated cirrhosis remains limited due to persistent safety concerns about potential decompensation and ...
Qiran Zhang +32 more
wiley +1 more source
ObjectivesTo systematically evaluate the efficacy and safety of tenofovir and entecavir in chronic hepatitis B-related cirrhosis.MethodsA comprehensive search was conducted in databases including PubMed, Web of Science, Embase and Cochrane Library from ...
Lu Cao +4 more
doaj +1 more source
HPV42 – a human papillomavirus classified as a low‐risk type with oncogenic potential
Summary Human papillomavirus (HPV) type 42 is a rare HPV type currently classified as “low‐risk” and belongs to the alpha genus. It has primarily been detected in benign vulvar papillomas and is predominantly associated with benign lesions such as anogenital warts.
Sven Niklas Burmann +7 more
wiley +1 more source
Human Vault Nanoparticle Targeted Delivery of Antiretroviral Drugs to Inhibit Human Immunodeficiency Virus Type 1 Infection. [PDF]
"Vaults" are ubiquitously expressed endogenous ribonucleoprotein nanoparticles with potential utility for targeted drug delivery. Here, we show that recombinant human vault nanoparticles are readily engulfed by certain key human peripheral blood ...
Anton, Peter A +11 more
core
Nevirapine versus Efavirenz for patients co-infected with HIV and Tuberculosis: A Randomised Non-Inferiority Trial [PDF]
BACKGROUND: In countries with a high incidence of HIV and tuberculosis co-infection, nevirapine and efavirenz are widely used as antiretroviral therapy but both interact with antituberculosis drugs. We aimed to compare efficacy and safety of a nevirapine-
Agnès Sobry +39 more
core +3 more sources
Indoleamine 2,3‐dioxygenase (IDO) activity modulates immune responses to the therapeutic HBV vaccine NASVAC. Genetic or pharmacological suppression of IDO enhanced vaccine efficacy in mice, and lower serum kynurenine levels predicted favorable responses in humans, suggesting IDO as both a therapeutic target and a biomarker.
Yohei Shirakami +15 more
wiley +1 more source
Tenofovir induced lichenoid drug eruption
Cutaneous adverse reactions are a common complication of anti-retroviral therapy. Tenofovir is a newer anti-retroviral drug belonging to the nucleotide reverse transcriptase inhibitor group.
Mrinal Gupta, Heena Gupta, Anish Gupta
doaj +1 more source
Abstract Objectives This study assessed real‐world effectiveness and safety of switching to dual therapy regimens consisting of an integrase inhibitor (INSTI), and reverse transcriptase inhibitor (RTI), among suppressed people living with HIV in Europe.
Cristina Mussini +24 more
wiley +1 more source

